Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen) for Treatment of Congenital Plasminogen Deficiency

Results from pivotal phase 2/3 study met co-primary endpoints for improvement in trough plasminogen activity levels and reduction in lesion size Pending approval, potential for Ryplazim® (plasminogen) to be first FDA-approved therapy for treatment of congenital plasminogen deficiency...

from PR Newswire: https://ift.tt/3h5oVh3